BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Liquidia Corporation readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Liquidia Corporation's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07748000-521@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Treprostinil (Yutrepia\, Liquidia): Phase 2 readout est. (NCT077480
 00)
DESCRIPTION:Treprostinil (Yutrepia\, Liquidia)\, phase 2\, Systemic Scleros
 is.\nStudy: A Study of LIQ861 (Inhaled Treprostinil) in Adults With System
 ic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks\nEstimated 
 primary completion: February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/treprostinil-yutrepia-liquidia#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07748000
URL:https://assetmemo.bio/drug/treprostinil-yutrepia-liquidia#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285655-522@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Treprostinil (L606): Phase 3 readout est. (NCT07285655)
DESCRIPTION:Treprostinil (L606)\, phase 3\, Pulmonary Hypertension Associat
 ed with Interstitial Lung Disease.\nStudy: A Phase 3 Study to Evaluate the
  Safety and Efficacy L606 in Participants With PH-ILD\nEstimated primary c
 ompletion: July 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /treprostinil-l606#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07285655
URL:https://assetmemo.bio/drug/treprostinil-l606#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
